55467-95-3

Upstream product

• 109-70-6 1.3-chlorobromopropane 
• 62-53-3 aniline 
• 6940-76-7 1-iodo-3-chloro-propane 

Downstream Products

• 87962-87-6 4-(phenylamino)butanoic acid 
• 1285616-79-6 N-(3-chloropropyl)-4-fluoro-N-phenylbenzenesulfonamide 
• 1285616-75-2 N-(3-chloropropyl)-4-fluoro-N-phenylbenzamide 
• 1285616-70-7 N-(3-chloropropyl)-N-phenylbenzamide 
• 1285616-73-0 4-chloro-N-(3-chloropropyl)-N-phenylbenzamide 
• 1285616-78-5 N-(3-chloropropyl)-N-phenylbenzenesulfonamide 
• 1285616-84-3 N-phenyl-N-(3-(4-phenylpiperazin-1-yl)-propyl)-benzamide 
• 1285616-86-5 N-phenyl-N-(3-(4-p-tolylpiperazin-1-yl)-propyl)benzamide 
• 1285616-87-6 4-chloro-N-phenyl-N-(3-(4-p-tolylpiperazin-1-yl)-propyl)-benzamide 
• 1285616-91-2 N-(3-(4-methylpiperazin-1-yl)-propyl)-N-phenylbenzamide 
• 1285616-93-4 N-phenyl-N-(3-(4-p-tolylpiperazin-1-yl)-propyl)-benzenesulfonamide 
• 1285616-95-6 4-fluoro-N-phenyl-N-(3-(4-p-tolylpiperazin-1-yl)-propyl)-benzenesulfonamide 
• 1285616-96-7 4-fluoro-N-(3-(4-(4-fluorophenyl)-piperazin-1-yl)-propyl)-N-phenylbenzamide 
• 1285616-97-8 4-fluoro-N-phenyl-N-(3-(4-p-tolylpiperazin-1-yl)-propyl)-benzamide 

Relevant academic research and scientific papers

Substituted piperazines as novel potential radioprotective agents

The increasing risk of radiation exposure underlines the need for novel radioprotective agents. Hence, a series of novel 1-(2-hydroxyethyl)piperazine derivatives were designed and synthesized. Some of the compounds protected human cells against radiation-

Design, synthesis, and biological evaluation of novel 2-methylpiperazine derivatives as potent CCR5 antagonists

Three series of novel 2-methylpiperazine derivatives were designed and synthesized using a fragment-assembly strategy. Among them, six compounds (13, 16, 18, 22, 33, and 36) showed potent activity against CCR5 comparable to that of the positive control, maraviroc, in calcium mobilization assay. Moreover, some compounds were selected and further tested for their antiviral activity in HIV-1 single cycle assay. As a result, four compounds (13, 16, 33, and 36) showed antiviral activity at the nanomolar level. Additionally, the potent four compounds showed no cytotoxicity at a concentration of 10 μM.

Synthesis and biological evaluation of novel N-[3-(4-phenylpip-erazin-1-yl) -propyl]-carboxamide derivatives

A series of novel N-[3-(4-phenylpiperazin-1-yl)-propyl]-carboxamide derivatives were synthesised and studied for the potential treatment of HIV. These compounds were obtained through the efficient synthetic route that involved microwave assisted synthesis. These new compounds have been characterised by IR,1H NMR, MS and elemental analysis. The cell-cell fusion inhibitory activities of the compounds have also been evaluated.

Heterocyclic antiviral compounds

Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R1-R3 R6c and X1 are as defined herein are antagonists of chemokine CCR5 receptors which ar

4,4'-Di-tert-butylbiphenyl-Catalysed Reductive Opening of Azetidines with Lithium: A Direct Preparation of 3,N-Dilithioalkylamines

The reaction of N-phenylazetidine 1a with an excess of lithium powder and a catalytic amount of 4,4'-di-tert-butylbiphenyl (5 molpercent) in THF at -15 deg C leads to the corresponding dianion 2a, which by treatment with different electrophiles (H2O, D2O, ButCHO, PhCHO, (CH2)5CO, PhCH=NPh, CO2) yields, after hydrolysis with water, the expected functionalysed amines 3aa-ah.The same method applied to N-isopropyl-2-phenylazetidine 1c affords compounds 3ca-ce (electrophiles: H2O, D2O, PhCHO, Me2CO, CH2=CHCH2Br) resulting from the more stable benzylic intermediate 2c.Finally, the regiochemistry in the reductive opening of 2-methyl-N-phenylazetidine 1d followed by deuterolysis was studied: a mixture of both regioisomers 3da+3da' was obtained, the ratio being the oposite as expected according to the stability of both intermediates 2d and 2d'.